{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-347853","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2026-08-13T11:05:15+00:00","discovered_at":"2026-08-13T11:10:06.605200+00:00","generated_at":"2026-08-13T11:10:21.312286+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Olema Pharmaceuticals appoints Jason O'Byrne as CFO, effective Aug 11, 2026","bullets":["O'Byrne previously CFO at Vir Biotechnology (2024-2026) and Caribou Biosciences (2021-2024); joins Olema from Vir.","Compensation: $545,000 base salary, 45% target bonus, $250,000 sign-on bonus plus $100,000 at 1-year anniversary.","Granted option for 650,000 shares under 2022 Inducement Plan, vesting over 4 years (25% at 1-year, then monthly).","Company cites upcoming pivotal OPERA-01 data and first potential commercial launch; highlights palazestrant and OP-3136."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-347853","json":"https://secwatch.observer/filing/0001193125-26-347853.json","markdown":"https://secwatch.observer/filing/0001193125-26-347853.md","text":"https://secwatch.observer/filing/0001193125-26-347853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526347853/0001193125-26-347853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526347853/olma-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:10:21.312286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}